Roivant Sciences Revenue and Competitors
Estimated Revenue & Valuation
- Roivant Sciences's estimated annual revenue is currently $57M per year.
- Roivant Sciences's estimated revenue per employee is $193,750
- Roivant Sciences's total funding is $2.1B.
- Roivant Sciences's current valuation is $7B. (May 2021)
Employee Data
- Roivant Sciences has 294 Employees.
- Roivant Sciences grew their employee count by -7% last year.
Roivant Sciences Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $15.3M | 99 | -49% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.5M | 29 | -6% | N/A | N/A |
#10 | $9.6M | 62 | -7% | N/A | N/A |
What Is Roivant Sciences?
Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants ? nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology. We have built 15 Vants to date and have raised over $3 billion to pursue our mission. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson?s disease, diabetes, sickle cell disease, and multiple rare and fatal pediatric conditions. We focus on disease areas where the magnitude of R&D investment from industry is disproportionately low relative to societal medical needs. In addition to our biopharmaceutical subsidiaries, we also build technology-focused Vants focused on improving the process of developing and commercializing medicines.
keywords:N/A$2.1B
Total Funding
294
Number of Employees
$57M
Revenue (est)
-7%
Employee Growth %
$7B
Valuation
N/A
Accelerator
Roivant Sciences News
Roivant Sciences Ltd. (NASDAQ:ROIV) Expected to Announce Quarterly Sales of $15.41 Million. Posted by admin on Apr 16th, 2022.
Wall Street brokerages predict that Roivant Sciences Ltd. (NASDAQ:ROIV Get Rating) will report ($0.25) earnings per share (EPS) for the...
... 2022 (GLOBE NEWSWIRE) -- Roivant Social Ventures, a nonprofit philanthropic social impact organization launched by Roivant Sciences,...
BASEL, Switzerland and LONDON and NEW YORK, Sept. 21, 2021 /PRNewswire/ -- Roivant Sciences Ltd. ("Roivant" or the "Company"), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, today reported its financial results for the fiscal quarter en ...
NEW YORK and BASEL, Switzerland, June 9, 2021 /PRNewswire/ -- Roivant Sciences today announced that Datavant, the leader in helping healthcare organizations securely connect their data, and Ciox Health, the leader in clinical data exchange, have signed a definitive merger agreement. The combine ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $93M | 338 | 32% | N/A |
#2 | $109.2M | 397 | 29% | N/A |
#3 | $63.4M | 409 | 4% | N/A |
#4 | N/A | 424 | 52% | N/A |
#5 | N/A | 623 | 21% | N/A |
Roivant Sciences Executives
Name | Title |
---|---|
Vivek Ramaswamy | Founder & CEO |
Mayukh Sukhatme | President & Chief Investment Officer |
Srini Ramanathan | Chief Development Officer |
Roger Sidhu | Executive Vice President, Head of Research and Development and Chief Medical Officer |
Srini Ramanathan | Chief Development Officer |
Matthew Gline | Chief Executive Officer |
Benjamin Pham | Chief of Staff |
Josephine Felipe | Executive Assistant to the Founder and CEO |
Regina Sav | Executive Assistant to the CFO |
Paul Davis | Chief Communications Officer |
Eric Venker | President and Chief Operating Officer |
Matt Hewmaisak | Chief Operating Officer, Roivant Platforms |
Drew Fromkin | Chief Executive Officer Proteovant, Vant Portfolio Operating Partner (Roivant Sciences) |
Drew Kramer | Chief Information Officer |
Regina Sav | Executive Business Partner, Office of the CEO |
Rakhi Kumar | Chief Accounting Officer |
Richard Pulik | Chief Financial Officer |
Mayukh Sukhatme | President & Chief Investment Officer |
Manish Ponda | Vice President, Clinical Development |
Roger Sidhu | Executive Vice President, Head of Research and Development and Chief Medical Officer |
Keith Haan | Vice President, Investments |
Jason Imbriglio | VP - Head of Platform Technology |
Joe Bishop | VP of Finance |
Sanjeev Kothari | Senior Vice President, CMC and Supply Chain |
Jian-ping Tang | Vice President, Head of Clinical Pharmacology |
Nanxiang Ge | VP, Head of Biometrics and Data Management |
Jon Kluft | VP Business Development |
Benjamin Zimmer | President, Roivant Health |
Eric Venker | President and Chief Operating Officer |
Matthew Blischak | Vice-President, Intellectual Property Counsel |
Nik Khetarpal | VP |
Alex Gasner | Executive Vice President, Roivant Health |
Eric Valeur | VP Research, Head of Drug Discovery |
Raj Punwaney | Vice President, Clinical Development |